Syndax Pharmaceuticals Inc Asset Resilience Ratio
Syndax Pharmaceuticals Inc asset resilience ratio. Syndax Pharmaceuticals Inc (SNDX) has an Asset Resilience Ratio of 30.04% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SNDX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Syndax Pharmaceuticals Inc (2011–2025)
Asset resilience ratio of Syndax Pharmaceuticals Inc from 2011 to 2025. This chart shows how Syndax Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read SNDX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Syndax Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Syndax Pharmaceuticals Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $211.38 Million | 30.04% |
| Total Liquid Assets | $211.38 Million | 30.04% |
Asset Resilience Insights
- Very High Liquidity: Syndax Pharmaceuticals Inc maintains exceptional liquid asset reserves at 30.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Syndax Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Syndax Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Syndax Pharmaceuticals Inc Asset Resilience Ratio by Year (2011–2025)
Syndax Pharmaceuticals Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Syndax Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.62% | $278.76 Million | $529.71 Million | -6.54pp |
| 2024-12-31 | 59.16% | $428.83 Million | $724.82 Million | +13.12pp |
| 2023-12-31 | 46.04% | $282.19 Million | $612.88 Million | -36.42pp |
| 2022-12-31 | 82.46% | $410.04 Million | $497.24 Million | +32.46pp |
| 2021-12-31 | 50.01% | $224.87 Million | $449.66 Million | -9.15pp |
| 2020-12-31 | 59.15% | $177.82 Million | $300.61 Million | +3.80pp |
| 2019-12-31 | 55.36% | $35.17 Million | $63.52 Million | -0.81pp |
| 2018-12-31 | 56.16% | $47.14 Million | $83.94 Million | -12.94pp |
| 2017-12-31 | 69.11% | $94.81 Million | $137.19 Million | -5.64pp |
| 2016-12-31 | 74.75% | $81.49 Million | $109.01 Million | +3.43pp |
| 2015-12-31 | 71.32% | $64.11 Million | $89.90 Million | +54.16pp |
| 2014-12-31 | 17.16% | $2.20 Million | $12.82 Million | -7.22pp |
| 2013-12-31 | 24.38% | $4.16 Million | $17.06 Million | +18.36pp |
| 2012-12-31 | 6.03% | $91.00K | $1.51 Million | -6.78pp |
| 2011-12-31 | 12.81% | $613.00K | $4.79 Million | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more